Dawley rat and human), 2) the metabolism kinetics of ATZ given as a bolus gavagevs. distributed dietary dose, and 3) the effect of gavage (bolus) vs. dietary (distributed)dose administration on the suppression of the luteinizing hormone (LH) surge inrats administered high doses of ATZ via gavage. Studies per<strong>for</strong>med in rat or humanhepatocytes and in intact Sprague-Dawley female rats showed rapid kinetics of ATZoxidative metabolism. Rat hepatocytes mainly converted ATZ to its desisopropylmetabolite (DIA) whereas the human hepatocytes preferentially converted ATZ toits desethyl metabolite (DEA). Both rat and human hepatocytes further metabolizedDIA and DEA to the diaminochloro metabolite (DACT). Comparison of chlorotriazineplasma concentrations after bolus vs. distributed dosing (equivalent doses)showed that peak concentrations of all analytes from the bolus dosing were 10-foldgreater than the peak concentrations from distributed administration of ATZ. Distributeddietary administration of ATZ <strong>for</strong> four days did not suppress the LH surgeat 500 ppm (43 mg/kg/day) whereas a single bolus gavage dose of 50 mg/kg/day<strong>for</strong> four days suppressed the LH surge (consistent with published data). The resultsindicate that the pharmacodynamics of ATZ is dependent upon the pharmacokineticsand the method of dose administration. These data were utilized to refine anexisting ATZ PBPK model to estimate internal doses in rat, non-human primates,and humans.128T2-J.2 King DB; drdavidbking@gmail.comFDA CBERMODELING THE SAFETY AND EFFICACY OF VACCINES THROUGHTHE LIFE CYCLEThe U.S. Food and Drug Administration (FDA) uses a multi-layered system ofregulations involving both pre-market clinical trials and multiple post-market safetysurveillance systems to ensure that the benefits of the influenza vaccine clearly exceedthe risks. There has been much research into the per<strong>for</strong>mance of individualcomponents of the FDA system <strong>for</strong> evaluating safety and efficacy; however, we arenot aware of any research that examines how effectively the overall system per<strong>for</strong>ms.Our project takes a systems approach to improve our understanding of the FDAevaluation system. We are developing a computer simulation of the FDA lifecycleevaluation system <strong>for</strong> influenza vaccines that will serve as a framework <strong>for</strong> rapid explorationof the functional relationship between regulatory decisions and the risk /benefit balance in terms of overall public health impact. To help model variousrisks and benefits, we have designed a computer simulation model based on a set ofstochastic differential equations similar to the standard Susceptible Exposed InfectiveRecovered disease model and which will simulate the disease dynamics taking placein the overall population. The model simulates the spread of influenza epidemicsgiven a certain a set of pre-defined characteristics associated with both the vaccineand virus. High per<strong>for</strong>mance computing is utilized both to simulate many hypotheticalflu seasons as well as to implement Bayesian Markov Chain Monte Carlo inferenceprocedures. Our model utilizes stochastic state space methodology whereby thenumber of people in each disease state is governed by the system model and a secondmeasurement model relates the noisy measurements to the state of the system. Forparameter estimation, our model makes use of a Bayesian approach to dynamic stateestimation <strong>for</strong> partially observed Markov processes whereby we construct a posteriorprobability <strong>for</strong> the state given the observed. Simulation results and methods will bediscussed <strong>for</strong> several case scenarios.M4-C.3 Kirman CR, Hays SM, Aylward LL*, Ramasamy S, Schoeny R; schoeny.rita@epa.govSummit Toxicology, US Environmental Protection AgencyINTERPRETING NHANES DATA ON ARSENIC LEVELS IN URINEUSING BIOMONITORING EQUIVALENTSThe National Health and Nutrition Examination Survey (NHANES) reporteddata on concentrations of speciated and total arsenic in urine <strong>for</strong> a sample of the generalpopulation. Adverse effects associated with arsenic exposures are thought to befrom exposure to inorganic species, which are excreted in urine in a variety of <strong>for</strong>ms:inorganic arsenic (iAs), monomethyl arsenic (MMA), and dimethyl arsenic (DMA). ABiomonitoring Equivalent (BE) has been derived <strong>for</strong> inorganic-derived arsenic speciesin urine, which provides an estimate of the concentration of iAs, MMA, DMAand their sums in urine that are consistent with reference values, such as the US EPAreference dose (BERfD). The BE can be used to interpret the arsenic biomonitoringdata in the context of the RfD. The sum of all inorganic derived arsenic species (iAs,MMA and DMA) from the NHANES 2007-8 collection period exceed the BERfDat around the 50th percentile, although the proportion exceeding the BERfD wasaffected by the treatment of non-detects. A significant proportion of the summedurine concentrations is due to DMA, which is assumed to result predominantly fromexposure to inorganic arsenic exposure. However, the NHANES biomonitoring dataindicate a correlation between DMA and seafood-derived organic arsenic species (arsenocholineand arsenobetaine), suggesting that DMA in urine may also arise fromseafood consumption. When DMA is omitted from summed inorganic arsenic species(sum of iAs and MMA), 90% of the NHANES biomonitoring data are belowthe BERfD. The BE associated with the 1E-4 cancer risk is a factor of ten lowerthan the BERfD and is below the limit of detection <strong>for</strong> the NHANES analyses. Thispresentation will explore the various advantages and disadvantages of analyzing thevarious arsenic species in urine in a risk assessment context and make recommendations<strong>for</strong> future ef<strong>for</strong>ts. The opinions are those of the authors and do not necessarilyreflect policies of U.S. EPA.
M4-C.1 Koch HM, Angerer J; koch@ipa-dguv.deInstitute <strong>for</strong> Prevention and Occupational Medicine (IPA), Ruhr-University BochumDEVELOPMENT AND USE OF TOXICITY BASED HUMAN BIOMON-ITORING (HBM) VALUES BY THE GERMAN HUMAN BIOMONI-TORING COMMISSIONHuman biomonitoring (HBM) data is a very useful metric <strong>for</strong> assessing human’sexposures to chemicals in commerce. To assess the potential health risks associatedwith the presence of chemicals in blood, urine or other biological matrix requiresHBM assessment values. While HBM assessment values based on human exposureresponsedata remain the most highly valuable and interpretable assessment values,enough data exists <strong>for</strong> such values <strong>for</strong> very few chemicals. As a consequence, ef<strong>for</strong>tshave been undertaken to derive HBM assessment values in which external dose basedguidance values such as Tolerable Daily Intakes have been translated into equivalentbiomonitoring levels. The development of HBM values by the German HBM Commissionand Biomonitoring Equivalents by Summit Toxicology has resulted in conceptuallysimilar assessment values. The review of the development of these valuesprovided here demonstrates examples and approaches that can be used to broadenthe range of chemicals <strong>for</strong> which such assessment values can be derived. Ef<strong>for</strong>ts todate have resulted in the publication of HBM assessment values <strong>for</strong> more than 80chemicals, and now provide tools that can be used <strong>for</strong> the evaluation of HBM dataacross chemicals and populations.W4-E.2 Kokotovich AE, Kuzma J; koko0013@umn.eduUniversity of MinnesotaEXAMINING THE POTENTIAL FUTURES OF PLANT TARGETEDGENETIC MODIFICATIONFrom anticipatory governance to the study of plausibility, how experts involvedwith emerging technologies conceive of possible futures <strong>for</strong> these technologies is ofgrowing importance. Practically with regards to risk analysis, identifying plausiblerisks is essential to the problem <strong>for</strong>mulation step of risk assessment, as only identifiedrisk hypotheses can be further examined. More broadly, how experts discern amongpotential futures influences what meanings of and concerns around these technologieswill be privileged and marginalized. Recent work has emphasized the importanceof examining the conflicting futures offered <strong>for</strong> these technologies by interrogatingthe differing logics and understandings that underpin these futures (e.g., Selin 2008).We contribute to this growing area of work through a study of experts involved withthe targeted genetic modification (TagMo) of plants. Targeted genetic modificationis a novel genetic engineering technique that employs homologous recombinationand has the potential, in plants, to allow <strong>for</strong> the genetic engineering of new traits andnew organisms. In this paper, we present the findings from 30 in-depth interviewswith a variety of plant TagMo experts, from those developing the technology to thosethinking about its potential societal impacts. Through these interviews, we asked:what potential futures and concerns do experts articulate concerning TagMo plantproducts? What differences underlie conflicting futures? We pay particular attentionto how interviewees rein<strong>for</strong>ce and challenge risk analysis frameworks as a means tostudy the potential harms from TagMo plant products. Our findings point to neededareas <strong>for</strong> reflection as TagMo plant products become addressed through ecologicalrisk assessment and governance processes. Additionally, we provide insights on thechallenges that a diversity of expert views poses <strong>for</strong> risk analysis.P.34 Kotani K, Managaki S, Masunaga S; kotani-kensuke-sc@ynu.ac.jpYokohama National UniversityA STUDY ON ALTERNATIVE RISK ASSESSMENT SCHEME OFFRAME RETARDANTSWhen a chemical is identified to impact on human health or poses ecologicalrisk, it might be banned and replaced depending on availability of substitutes.With such a replacement policy, risk from the replaced chemical is naturally reduced,but risk from its substitute increases. This is called risk-trade-off between replacedchemical and its substitute. It is important to prove that the substitute chemical posesless risk than the one it replaced. In which case, how can we compare the risk ofreplaced chemical and its substitute? In this study, we focused on a frame retardant,Hexabromocyclododecane (HBCD) and assumed its substitutes as a case study ofalternative risk assessment <strong>for</strong> chemicals in consumer products. This research hastwo objects; first, to predict exposure volume using mathematical models on alternativescenario. And second, to investigate variation in outcome when different riskassessment methods are used. To achieve the first objective, exposure assessment onalternative scenario was undertaken within a framework of uni<strong>for</strong>m incombustibilitybetween HBCD and its substitutes. If emission rate from products of replacedchemical is known, it is possible to estimate that of the substitute. Exposure volumeof the substitute could also be estimated based on in<strong>for</strong>mation of per<strong>for</strong>mance offrame retardant and physico-chemical property. To achieve the second objective, wecompared the results of deterministic risk assessment and probabilistic risk assessment.The method of deterministic risk assessment provided in<strong>for</strong>mation regardingwhether risk exists or not on average or worst scenario. On the other hand methodof probabilistic risk assessment quantified in detail if probability of exposure volumeexceed reference-dose (RfD). The findings suggested that each approach might leadto a different conclusion.129
- Page 4 and 5:
Ballroom C1Monday10:30 AM-NoonM2-A
- Page 9 and 10:
US Environmental Protection Agency
- Page 11 and 12:
Workshops - Sunday, December 4Full
- Page 13 and 14:
WK9: Eliciting Judgments to Inform
- Page 15 and 16:
These freely available tools apply
- Page 17 and 18:
Plenary SessionsAll Plenary Session
- Page 19 and 20:
10:30 AM-NoonRoom 8/9M2-F Panel Dis
- Page 21 and 22:
1:30-3:00 PMRoom 8/9M3-F Symposium:
- Page 23 and 24:
4:50 pm M4-E.5Modeling of landscape
- Page 25 and 26:
P.35 Health risk assessment of meta
- Page 27 and 28:
Works-In-ProgressP.99 Assessing the
- Page 29 and 30:
10:30 AM-NoonRoom 8/9T2-F Error in
- Page 31 and 32:
1:30-3:00 PMRoom 8/9T3-F AppliedMet
- Page 34 and 35:
8:30-10:00 AMBallroom C1W1-A Sympos
- Page 36 and 37:
10:30 AM-NoonBallroom C1W2-A Commun
- Page 38:
1:30-3:00 PMBallroom C1W3-A Communi
- Page 41 and 42:
3:30-4:30 PMRoom 8/9W4-F Environmen
- Page 43 and 44:
oth recent advances, and ongoing ch
- Page 45 and 46:
M3-H Symposium: Analyzing and Manag
- Page 47 and 48:
Part 2, we consider the use of expe
- Page 49 and 50:
T4-E Symposium: Food Safety Risk Pr
- Page 51 and 52:
While integral to guiding the devel
- Page 53 and 54:
have contributed to past difficulti
- Page 55 and 56:
M2-C.1 Abraham IM, Henry S; abraham
- Page 58 and 59:
serious accident of the Tokyo Elect
- Page 60 and 61:
een found that independence assumpt
- Page 62 and 63:
W4-I.1 Beach RH, McCarl BA, Ohrel S
- Page 64 and 65:
M4-A.1 Berube DM; dmberube@ncsu.edu
- Page 66 and 67:
W4-A.1 Boerner FU, Jardine C, Dried
- Page 69 and 70:
M2-G.1 Brink SA, Davidson RA; rdavi
- Page 71 and 72:
M4-H.5 Buede DM, Ezell BC, Guikema
- Page 73 and 74:
same scientists’ environmental he
- Page 75 and 76:
periods of time. Successful adaptat
- Page 77 and 78:
P.123 Charnley G, Melnikov F, Beck
- Page 79 and 80: derived from mouse and rat testes t
- Page 81 and 82: esources under any circumstance in
- Page 83 and 84: W4-B.3 Convertino M, Collier ZA, Va
- Page 85 and 86: addition, over 10% thought that eve
- Page 87 and 88: Reference Dose (RfD). The average e
- Page 89 and 90: W2-H.2 Demuth JL, Morss RE, Morrow
- Page 91 and 92: T4-H.4 Dingus CA, McMillan NJ, Born
- Page 93 and 94: methods research priorities and pot
- Page 95 and 96: W3-A.2 Eggers SL, Thorne SL, Sousa
- Page 97 and 98: tions) were < 1 for sub-populations
- Page 99 and 100: sociated with model error. Second,
- Page 101 and 102: inter-donation interval to mitigate
- Page 103 and 104: Fukushima nuclear accident coverage
- Page 105 and 106: for growth inhibitor use and retail
- Page 107 and 108: W1-C.1 Goble R, Hattis D; rgoble@cl
- Page 109 and 110: stakeholders. The utility of this m
- Page 111 and 112: T2-E.4 Guidotti TL; tee.guidotti@gm
- Page 113 and 114: M4-C.2 Haines DA, Murray JL, Donald
- Page 115 and 116: providing normative information of
- Page 117 and 118: then allow both systems to operate
- Page 119 and 120: tious disease outbreaks. Several cl
- Page 121 and 122: P.122 Hosseinali Mirza V, de Marcel
- Page 123 and 124: W2-B.1 Isukapalli SS, Brinkerhoff C
- Page 125 and 126: M3-G.3 Jardine CG, Driedger SM, Fur
- Page 127 and 128: P.88 Johnson BB, Cuite C, Hallman W
- Page 129: metrics to provide risk management
- Page 133 and 134: certainty factors) and comparative
- Page 135 and 136: T3-D.4 LaRocca S, Guikema SD, Cole
- Page 137 and 138: P.71 Lemus-Martinez C, Lemyre L, Pi
- Page 139 and 140: of excretion, and the increased che
- Page 141 and 142: M2-D.4 MacKenzie CA, Barker K; cmac
- Page 143 and 144: isk appetite and optimal risk mitig
- Page 145 and 146: ameters, and enabled a more robust
- Page 147 and 148: over the nature and format of infor
- Page 149 and 150: Analysis (PRA). Existing parametric
- Page 151 and 152: explosion of a bomb in a building,
- Page 153 and 154: T3-G.3 Nascarella MA; mnascarella@g
- Page 155 and 156: corresponding slowdown in container
- Page 157 and 158: ing the scope and usage of the cybe
- Page 159 and 160: dose for a variety of exposure scen
- Page 161 and 162: “nanofibers”) is relatively und
- Page 163 and 164: ment (CEA), which provides both a f
- Page 165 and 166: T3-D.2 Resurreccion JZ, Santos JR;
- Page 167 and 168: shore wind turbines have yet been b
- Page 169 and 170: T2-D.3 Rypinski AD, Cantral R; Arth
- Page 171 and 172: time and temperature, determining t
- Page 173 and 174: esponse to requests from the EC, th
- Page 175 and 176: ers and inspectors. Analysis examin
- Page 177 and 178: smoked salmon, and associated expos
- Page 179 and 180: and 95th percentiles). Increasing t
- Page 181 and 182:
esponse relationship for B. anthrac
- Page 183 and 184:
variation on Day 0. Results showed
- Page 185 and 186:
sidered. The most significant resul
- Page 187 and 188:
lived in a apartment (not including
- Page 189 and 190:
W3-C.4 von Stackelberg KE; kvon@eri
- Page 191 and 192:
P.12 Waller RR, Dinis MF; rw@protec
- Page 193 and 194:
W2-B.6 Wang D, Collier Z, Mitchell-
- Page 195 and 196:
iomonitoring “equivalent” level
- Page 197 and 198:
T4-H.2 Winkel D, Good K, VonNiederh
- Page 199 and 200:
mation insufficiency, risk percepti
- Page 201 and 202:
choices. This work examines these s
- Page 203 and 204:
sults and possible intended or unin
- Page 205 and 206:
AAbadin HG.................... 36,
- Page 207 and 208:
Gray GM............................
- Page 209 and 210:
Peters E...........................
- Page 211 and 212:
SECOND FLOOR Floor MapConvention Ce